CERVICAL CANCER — GENETIC SUSCEPTIBILITY

Cervical Cancer Genetic Susceptibility — while HPV causes >95% of cervical cancers, host genetics determine whether HPV infection clears or persists, and HLA genotype is the strongest genetic factor influencing cervical cancer risk.

Whole genome sequencing determines HLA haplotypes (DRB1, DQB1) and evaluates immune response genes (IRF3, TERT, MHC class I/II) that influence HPV clearance and cervical cancer susceptibility — providing genetic risk stratification for screening optimization.

HLA-DRB1
HLA-DQB1
IRF3
TERT
KIR

About this condition

Cervical Cancer — Genetic Susceptibility

Cervical cancer is the fourth most common cancer in women worldwide, with persistent high-risk HPV infection (particularly HPV 16 and 18) causing >95% of cases. However, most HPV infections clear spontaneously — only a minority progress to cervical cancer. The difference between clearance and persistence is largely determined by host immune genetics. HLA class II genes (HLA-DRB1, HLA-DQB1) are the strongest genetic determinants — specific alleles (DRB1*13:01) are protective, while others (DRB1*15:01 for HPV 16, DQB1*03:01 for HPV 18) increase persistence risk.

Beyond HLA, additional immune response genes affect cervical cancer susceptibility. TERT variants influence telomere length and cellular immortalization following HPV integration. IRF3 (interferon regulatory factor 3) variants affect the innate immune response to viral infection. Killer immunoglobulin-like receptor (KIR) genes interact with HLA class I to determine NK cell-mediated clearance of HPV-infected cells. These host genetic factors explain why cervical cancer clusters in families independent of HPV exposure.

Genetic risk profiling for cervical cancer may have clinical utility in personalizing screening intervals. Women with high-risk HLA genotypes and positive HPV tests may benefit from more intensive colposcopic surveillance, while those with protective HLA genotypes may be safely screened at standard intervals. Additionally, genetic variation in the immune response may inform HPV vaccine response prediction and the development of therapeutic HPV vaccines currently in clinical trials.

Most HPV infections clear spontaneously — genetics determines who progresses to cancer. HLA-DRB1*13:01 is protective; DRB1*15:01 increases HPV16 persistence risk. Your immune genetics influence your cervical cancer risk beyond HPV status alone.

Gene locus: HLA-DRB1 (6p21.32), HLA-DQB1 (6p21.32), IRF3 (19q13.33), TERT (5p15.33), KIR (19q13.4)

HPV status tells you about the virus. HLA genotype tells you about your immune response. Together they provide the most accurate cervical cancer risk assessment — guiding personalized screening intensity.

HLA genotype determines HPV clearance vs. persistence — the critical step between infection and cancer

An HPV-positive woman with protective HLA genotypes has a high probability of viral clearance. An HPV-positive woman with susceptible HLA genotypes has a higher probability of viral persistence and progression. WGS determines complete HLA typing, enabling genetic risk stratification that complements HPV testing for personalized cervical cancer screening decisions.

Familial cervical cancer clustering is real — genetic immune profiling identifies women who need intensified screening

Women with a first-degree relative who had cervical cancer have approximately 2x increased risk — not because of shared HPV exposure, but because of shared immune genetics. WGS evaluates the HLA and immune gene variants that contribute to this familial risk, enabling risk-stratified screening for family members.

Cervical Cancer Genetic Susceptibility — while HPV causes >95% of cervical cancers, host genetics determine whether HPV infection clears or persists, and HLA genotype is the strongest genetic factor influencing cervical cancer risk.

Cervical Cancer — Genetic Susceptibility

HPV status tells you about the virus. HLA genotype tells you about your immune response. Together they provide the most accurate cervical cancer risk assessment — guiding personalized screening intensity.

HLA genotype determines HPV clearance vs. persistence — the critical step between infection and cancer

Familial cervical cancer clustering is real — genetic immune profiling identifies women who need intensified screening

Others in Hereditary Cancer

One test. A lifetime of answers.